Larimar Therapeutics, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Larimar amended its Certificate of Designation on January 21, 2026, to increase authorized Series A Convertible Preferred Stock from an unstated prior level to 500,000 shares (par value $0.001/share), drawn from the 5M authorized preferred shares under the Certificate of Incorporation. This is a structural capital authorization change; no issuance, conversion, or financing terms are disclosed in this exhibit.
Why this rating
Administrative capital authorization amendment; no actual capital raise, conversion, or dilution event disclosed. Enables future financing but routine for small biotech. Relative to $94.7M market cap, authorization alone is not economically material.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.